← Leaderboards
Paulo H. Verardi
University Of California Davis
$3,754,968
Attributed
$3,754,968
Total exposure
4
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $526.1K · FY2005–25$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,754,968 · 4
By mechanism
R01$2,523,497 · 1
R21$1,231,471 · 3
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Vaccine Development”
- Lawrence Corey · Fred Hutchinson Cancer Center$718,120,301
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$554,939,981
- Bambra Strokes · Ppd Development Lp$526,656,217
- Barton F Haynes · Duke University$394,383,754
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$392,263,550
- Dennis R. Burton · Scripps Research Institute$312,611,400
Research focus
Vaccine DevelopmentVaccinia VirusVaccinia Virus VectorGenesCell Culture TechniquesMouse ModelVaccinesImmunogenicityAntigensDesignVaccinatedVaccine CandidateVaccine EfficacyEfficacy TestingReportingNeutralizing AntibodySerumInterferon ReceptorElectron MicroscopyCell Mediated Immune ResponseKnockout MiceProtein ExpressionAnimal ModelImmunocompetent
Grant awards (11)
Vaccines for Prevention of RG3 and RG4 Emerging Tickborne Viral Diseases$499,355
R01 · FY2025 · AI · contact PI
Vaccines for Prevention of RG3 and RG4 Emerging Tickborne Viral Diseases$499,355
R01 · FY2024 · AI · contact PI
Vaccines for Prevention of RG3 and RG4 Emerging Tickborne Viral Diseases$499,355
R01 · FY2023 · AI · contact PI
Vaccines for Prevention of RG3 and RG4 Emerging Tickborne Viral Diseases$499,355
R01 · FY2022 · AI · contact PI
Vaccines for Prevention of RG3 and RG4 Emerging Tickborne Viral Deseases$526,077
R01 · FY2021 · AI · contact PI
Rapid development of replication-controlled vaccinia virus vectors for vaccines and therapeutics with single or double safety features$193,993
R21 · FY2018 · AI · contact PI
Rapid development of replication-controlled vaccinia virus vectors for vaccines and therapeutics with single or double safety features$219,298
R21 · FY2017 · AI · contact PI
Rapid development and testing of Zika virus vaccine candidates$192,254
R21 · FY2017 · AI · contact PI
Rapid development and testing of Zika virus vaccine candidates$217,551
R21 · FY2016 · AI · contact PI
SMART Virus Vectors with a Built-in Safety Mechanism$222,750
R21 · FY2005 · AI
SMART Virus Vectors with a Built-in Safety Mechanism$185,625
R21 · FY2004 · AI